Tekla Healthcare Opportunities Fund
Tekla Healthcare Opportunities Fund (THQ) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Tekla Healthcare Opportunities Fund (THQ), covering cash flow, earnings, and balance sheets.
Tekla Healthcare Opportunities Fund (THQ) Income Statement & Financial Overview
Analyze Tekla Healthcare Opportunities Fund’s THQ earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|
| Revenue | $14.22M | $62.13M | $18.38M | $50.83M |
| Cost of Revenue | $5.99M | $6.15M | $6.16M | $6.61M |
| Gross Profit | $8.23M | $55.98M | $12.22M | $44.22M |
| Gross Profit Ratio | $0.58 | $0.90 | $0.66 | $0.87 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | -$122.71M | $0.00 | $0.00 | $0.00 |
| Operating Expenses | -$122.71M | $57.47M | -$55.14M | $165.05M |
| Total Costs & Expenses | -$116.72M | $63.62M | -$48.98M | $171.66M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $7.52M | $7.24M | $5.85M | $2.57M |
| Depreciation & Amortization | $0.00 | $43812.00 | $122085.00 | $54880.00 |
| EBITDA | $130.94M | -$1.48M | $67.36M | -$120.83M |
| EBITDA Ratio | $9.21 | -$0.02 | $3.66 | -$2.38 |
| Operating Income | $130.94M | -$1.48M | $67.36M | -$120.83M |
| Operating Income Ratio | $9.21 | -$0.02 | $3.66 | -$2.38 |
| Other Income/Expenses (Net) | -$7.52M | -$7.24M | -$5.85M | -$2.57M |
| Income Before Tax | $123.42M | -$8.73M | $61.52M | -$123.39M |
| Income Before Tax Ratio | $8.68 | -$0.14 | $3.35 | -$2.43 |
| Income Tax Expense | $0.00 | -$43812.00 | -$122085.00 | -$54880.00 |
| Net Income | $123.42M | -$8.73M | $61.52M | -$123.39M |
| Net Income Ratio | $8.68 | -$0.14 | $3.35 | -$2.43 |
| EPS | $2.98 | -$0.21 | $1.49 | -$2.98 |
| Diluted EPS | $2.98 | -$0.21 | $1.49 | -$2.98 |
| Weighted Avg Shares Outstanding | $41.36M | $41.36M | $41.36M | $41.36M |
| Weighted Avg Shares Outstanding (Diluted) | $41.36M | $41.36M | $41.36M | $41.36M |
The company's financials show resilient growth, with revenue advancing from $50.83M in Q4 2022 to $14.22M in Q2 2024. Gross profit remained healthy with margins at 58% in Q2 2024 compared to 87% in Q4 2022. Operating income hit $130.94M last quarter, sustaining a consistent 921% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $130.94M. Net income rose to $123.42M, while earnings per share reached $2.98. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan